Eloralintide clinical trials and weight-loss research

A guide to eloralintide, its published Phase 2 weight-loss results, Phase 3 ENLIGHTEN studies and separate EloraTZP combination research.

By Manchester Peptides · Published 5 November 2026

What is eloralintide?

Eloralintide (LY3841136) is an investigational selective amylin receptor agonist being studied for weight management. Amylin signalling is involved in fullness and food intake. This target differs from the GIP and GLP-1 receptors targeted by tirzepatide, the active ingredient in Mounjaro, and the three receptors targeted by retatrutide.

Eloralintide remains investigational. The research programme includes eloralintide alone, eloralintide added to background incretin treatment, and a separate investigational combination called EloraTZP. Each design answers a different question.

Why researchers are looking at amylin for weight loss

The pancreas releases amylin after eating. The hormone is involved in satiety, the feeling of fullness. Lilly designed eloralintide to preferentially activate the amylin 1 receptor. This explains the biological rationale for studying eloralintide in obesity. The size of any clinical effect and the side effects still have to be measured in people. Read Lilly's mechanism and development summary.

Eloralintide weight loss in the published Phase 2 trial

The 48-week randomised, double-blind trial enrolled 263 adults with obesity, or overweight with a related condition, without type 2 diabetes. Across the studied eloralintide groups, mean weight loss ranged from 9.5% to 20.1%, versus 0.4% with placebo, using the efficacy estimand. This analysis estimates the expected effect under continued treatment conditions. The range describes averages in different study groups. Read the published Lancet study.

In the same paper, the treatment-regimen analysis found mean weight loss of up to 17.5% compared with 2.3% for placebo. That analysis accounts for events such as stopping treatment. Both results come from the same study and answer different questions.

The study found a weight-loss signal at 48 weeks. It had a smaller sample and shorter follow-up than some studies of licensed medicines. Reported adverse events included gastrointestinal symptoms and fatigue. The results leave open questions about weight maintenance, outcomes after stopping, and uncommon adverse effects.

Why does the same eloralintide trial report two different percentages?

The difference between each pair of numbers comes from the same study using different analysis questions. In a study with multiple groups, also check how much uncertainty surrounds each estimate. Smaller groups generally provide less precision. Figure 2 of the Lancet paper shows both analyses, along with the percentages of participants who reached different weight-loss thresholds.

This trial excluded type 2 diabetes. It did not randomise people between eloralintide and Mounjaro or retatrutide. How well eloralintide works in people with type 2 diabetes and how it compares with other treatments need different trials.

Eloralintide Phase 3 ENLIGHTEN studies

The trials are designed around different endpoints. In sleep apnoea research, the apnoea–hypopnoea index counts breathing interruptions per hour. The osteoarthritis trial uses a knee-pain scale. Changes in body weight, breathing interruptions and pain answer separate questions. Each should be checked against its own control group and follow-up period.

A registry entry records the study plan and status. Enrolment targets and estimated completion dates can change. Check the record's Results section or a journal publication for findings.

EloraTZP and tirzepatide: what the combination report means

In September 2026, Lilly reported Phase 2b results for EloraTZP, an investigational combination of eloralintide and tirzepatide. In 367 adults with type 2 diabetes and obesity or overweight, Lilly reported up to 23.3% mean weight loss with the combination and 14.8% with tirzepatide alone at 48 weeks. The sponsor also reported HbA1c reductions of up to 2.9 percentage points versus 2.4. Read the sponsor report.

That comparison concerns a defined study combination in a specific population. It cannot establish how eloralintide alone compares with Mounjaro, or how eloralintide compares with retatrutide. The numbers describe clinical research and provide no basis for combining products yourself.

What did the EloraTZP sponsor report say about tolerability?

Lilly's conference summary pooled safety data across 367 treated participants. Across the study arms, 77.7% reported at least one treatment-emergent adverse event, 6.5% reported a serious adverse event, and 11.4% stopped treatment because of an adverse event. Nausea, diarrhoea and constipation were among the most frequent reports. These pooled figures include several groups and cannot be assigned to eloralintide alone or to an individual combination arm. A treatment-emergent event occurs after treatment starts. Its timing alone does not establish causation. Read the sponsor's conference safety tables.

EloraTZP Phase 3 AMPLIFY studies

ENLIGHTEN-6 is an add-on study in people already receiving a stable incretin treatment. The AMPLIFY studies evaluate the investigational combination. Neither trial registration establishes effectiveness or authorisation. Study status and dates can change as the records are updated.

How to compare eloralintide weight-loss claims

Check whether the report studied eloralintide alone or the combination, whether participants had type 2 diabetes, what the comparison group received, and how the analysis handled people who stopped treatment. The side-by-side research comparison separates those questions for eloralintide, retatrutide and Mounjaro.